Ankyra Therapeutics
MA - CambridgeBiotechnology
Focus: Ankyra Therapeutics is a Cambridge-based biotechnology company focused on developing cytokine immunotherapies for oncology, currently in early-stage clinical development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Ankyra Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Ankyra Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
tolododekin alfa
Advanced Solid TumorClinical Trials (3)
NCT07027514A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Phase 1Help build intelligence for Ankyra Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.